Objective-In the reverse cholesterol transport pathway, high-density lipoprotein (HDL) passes the endothelial cell barrier by mechanisms involving the scavenger receptor class B type I and the ATP-binding cassette G1. However, little is known on how inflammation influences this transendothelial transport. Approach and Results-On stimulation with interleukin-6, cultivated primary endothelial cells showed increased binding and transport of 125 I-HDL without changing the expression of scavenger receptor class B type I and ATP-binding cassette G1. Therefore, we analyzed the involvement of endothelial lipase (EL), a known HDL-binding protein expressed by endothelial cells. Here, we show an increased EL expression after interleukin-6 stimulation. Moreover, using pharmacological inhibitors or RNA interference against EL, we demonstrated its participation in HDL binding and transport through the endothelium. Furthermore, adenovirus-mediated transfection of endothelial cells with either catalytically active or nonactive EL revealed that EL facilitates the endothelial binding and transport by both bridging and lipolysis of HDL. EL was also found responsible for the reduction of HDL particle size occurring during the specific transport through a monolayer of endothelial cells. Finally, pharmacological inhibition of EL reversed the inducing effect of interleukin-6 on HDL binding and transport. Conclusions-Interleukin-6 stimulates the translocation of HDL through the endothelium, the first step in reverse cholesterol transport pathway, by enhancing EL expression. In addition, we demonstrated the role of EL in the transendothelial transport of HDL. (Arterioscler Thromb Vasc Biol. 2013;33:2699-2706 .) The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A therosclerosis is a chronic disease characterized by lipid retention and inflammation in the arterial wall. Many studies revealed that the cholesterol concentration of plasma high-density lipoproteins (HDL) is inversely correlated with the risk of coronary artery disease events. 1 The cardioprotective role of HDL is, in part, related to its ability to remove cholesterol from macrophage foam cells in the arterial wall and carry it to the liver for excretion into the bile. 2 An early step in the reverse cholesterol transport is the transfer of cholesterol from macrophages to HDLs. Importantly, cholesterol efflux is not taking place in the plasma but in the arterial intima. 2 Consequently, HDL has to cross endothelial barriers twice to get access to the cholesterol-loaded macrophages and to re-enter the blood stream for cholesterol delivery to the liver. 3 Indeed 2 recent studies provided in vivo evidence that the transendothelial transport of HDL into the lymphatic vasculature is a rate-limiting step in reverse cholesterol transport. 4, 5 We previously demonstrated that endothelial cells bind, internalize, and transcytose HDL in a saturable and temperature-dependent manner. Using siRNA and pharmacological interferences, we demonstrated that endothelial cells bind and transport HDL by distinct specific mechanisms involving the scavenger receptor class B type I (SR-BI) and the ATP-binding cassette (ABC) transporter G1 but not ABCA1. 6 In inflammatory diseases, such as atherosclerosis, many cytokines, including tumor necrosis factor α, the interleukin (IL) 1β, and IL-6, have been demonstrated to be elevated in patient plasma. 7 Moreover, Hingorani and Casas 8 and Sarwar et al 9 recently demonstrated a relationship between the IL-6 receptor pathway and atherosclerosis. IL-6 has been also demonstrated to increase the cholesterol efflux to HDL in macrophages. 10 Consequently, we hypothesized that IL-6 may modulate the transendothelial transport of HDL. Indeed, here we provide evidences that IL-6 enhances the binding and transport of HDL in an SR-BI-and ABCG1-independent way. This observation raised the possibility that an additional protein is involved in the binding, internalization, and transport of HDL through endothelial cells. In a candidate-based approach, we investigated whether endothelial lipase (EL) is involved. EL is a member of the triglyceride lipase family that includes hepatic lipase and lipoprotein lipase. In contrast to hepatic lipase and lipoprotein lipase, vascular endothelial cells express and secrete EL, a glycoprotein of 68 kDA. Bound by extracellular proteoglycans, EL binds HDL, hydrolyzes HDL-phospholipids at the sn-1 position, and thereby regulates plasma levels of HDL-cholesterol. 11, 12 By its bridging or ligand-binding function, EL, such as hepatic lipase and lipoprotein lipase, facilitates the cellular binding and uptake of different lipoproteins. [13] [14] [15] [16] Moreover, several groups demonstrated the upregulation of EL on inflammatory stimulation both in vitro and in vivo. [17] [18] [19] [20] In this study, we provide evidence that EL participates in endothelial binding, cell association, and transport of HDL.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

IL-6 Induces HDL Binding, Cell Association, and Transport
To investigate whether the interaction of HDL with endothelial cells is changed by the inflammatory cytokine IL-6, we stimulated aortic endothelial cells with IL-6. The interaction of HDL with the endothelial cells was characterized as binding at 4°C, cell association and transport at 37°C. IL-6 induced HDL binding to endothelial cells in a dose-and timedependent manner ( Figure IA and IB in the online-only Data Supplement). HDL binding was significantly increased after incubation with 1-or 10-ng/mL IL-6. Because of the maximal effects seen, all subsequent experiments were performed on cells that were stimulated without 0-or 10-ng/mL IL-6 for 24 hours. After 24 hours of IL-6 stimulation, specific binding was induced by 200±67% compared with not stimulated cells (100±28%; Figure 1A ). Conversely, the specific cellularassociated HDL and the transported HDL were also increased by 144±21% and 178±39%, respectively, compared with not stimulated cells (100±17%; Figure 1B and 1C). Moreover, to rule out that the induction of HDL transport was because of permeability changes after IL-6 stimulation, the integrity of the endothelial cells monolayer was assessed by analyzing the permeability of 3 H-inulin. The tracer was added to the apical chamber, and the radioactivity in the basolateral chamber was counted. The permeability coefficient was not changed after IL-6 stimulation compared with the control, namely 1.756±0.156×10 -5 cm/s and 1.863±0.208×10 -5 cm/s ( Figure 1D ) for a time period of 1 hour. In addition, to analyze whether other inflammatory cytokines stimulate HDL binding to endothelial cells, the effect of tumor necrosis factor α and IL-1β was analyzed. Both cytokines induced HDL binding after 24 hours by 130±14% and 146±33%, respectively, compared with not stimulated cells 100% ± 17% ( Figure III Previously, we demonstrated that ABCG1 and SR-BI modulate the endothelial cell interaction with HDL. Therefore, we analyzed the mRNA level and protein expression of ABCG1 and SR-BI after IL-6 stimulation. Interestingly, real-time reverse transcriptase-polymerase chain reaction analysis did not demonstrate any significant changes in the expression levels of ABCG1 and SR-BI after IL-6 stimulation, namely 1.23±0.33-fold for SR-BI and 1.10±0.49-fold for ABCG1 , and transport of high-density lipoprotein (HDL; C), as well as permeability (D). Endothelial cells were stimulated with IL-6 (10 ng/mL) for 24 hours before the assays. Binding (A) was measured by incubating the cells with 10-μg/mL 125 I-HDL at 4°C. To analyze the association (B) and transport (C), endothelial cells were cultivated for 24 hours on insert before IL-6 stimulation then 125 I-HDL was added to the apical compartment. After 1 hour at 37°C cells were lysed, and specific activity was counted to obtain cell association (B). Medium of the basal compartment was harvested, and specific activity was monitored to obtain the transport (C). The permeability of the cell monolayer for insulin was determined (D). The results are represented as mean±SD of ≥3 individual experiments made of triplicate. ***P≤0.001, **P≤0.01. ns indicates not significant.
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relative expression compared with not stimulated cells set to 1 ( Figure IIA and IIB in the online-only Data Supplement). Moreover, Western blot analyses of the protein expression levels of ABCG1 and SR-BI after stimulation were not significantly changed (1.07±0.44-fold and 0.89±0.37-fold, respectively; Figure IIC and IID in the online-only Data Supplement). These results indicated that enhanced cell binding, association, and transport of HDL after IL-6 stimulation are independent of SR-BI and ABCG1.
Identification of EL-Modulating Transendothelial Transport
We hypothesized that EL mediates HDL binding, cell association, and transport. First, we confirmed the expression of EL in endothelial cells by polymerase chain reaction (data not shown) and by Western blot analysis (Figure 2A ). Then the effect of IL-6 stimulation on EL expression was analyzed. After 24 hours stimulation with IL-6, EL expression was doubled on both the RNA level (2.12±0.41-fold; Figure 2B ) and the protein level (1.98±0.84-fold; Figure 2C ) as revealed by real-time polymerase chain reaction and Western blotting analyses.
To evaluate the role of EL in HDL binding, we treated the cells with general pharmacological inhibitors, as well as by reducing its expression specifically through RNA interference. The binding of HDL was reduced to 79±10% after treatment of the cells with heparin. Moreover, after digesting the cell surface proteoglycans with heparinase, the binding of HDL was reduced to 65±15%. In addition, treating the cells with the general lipase inhibitor tetrahydrolipstatin reduced the binding to 53±22% compared with not stimulated cells (100±8%; Figure 3A ). Finally, specific RNA interference against EL reduced binding, association, and transport to 52±12% (100±6%) for binding, 71±14% (100±5%) for association, and 47±8% (100±9%) for transport ( Figure 3B -3D). On the transcriptional level, siRNA treatment led to a 90% decrease in EL mRNA expression (data not shown) and 50% decrease in EL protein level compared with noncoding siRNA transfected cells, whereas the expression of SR-BI and ABCG1 remained unchanged ( Figure 3E ). The binding of HDL to primary bovine microvascular endothelial cells and human aortic endothelial cells, as well as in the cell line EA.hy296, was reduced after tetrahydrolipstatin treatment to a similar extent as in bovine aortic endothelial cells (Figure IVA-IVC in the online-only Data Supplement). In addition, specific RNA against EL and tetrahydrolipstatin reduced HDL cell association in EA.hy926 cells ( Figure IVD and IVE) . These results indicate that EL modulates binding, association, and transport of HDL through endothelial cells.
Independent of the lipase activity EL, such as hepatic lipase and lipoprotein lipase, has a ligand-binding function enhancing plasma lipoprotein uptake into cells. 14 To investigate this so-called bridging function of EL, the HDL binding and transport properties of endothelial cells overexpressing either wildtype catalytic active EL (AD-EL) or a noncatalytic mutant of EL (AD-MUT EL) were analyzed. After adenoviral infection of the endothelial cells, the protein expression of wild-type EL, as well as mutated EL, was enhanced compared with the control cells infected with AD-LacZ ( Figure 4A ). As expected, cells infected with AD-EL but not cells infected with AD-MUT EL showed an increased lipolytic activity (677±75% versus 92±16%) compared with the control AD-LacZ (100±24%; Figure 4B ). Infecting the cells with AD-EL or AD-MUT EL increased HDL binding by 219±56% and 264±64%, respectively, compared with the control AD-LacZ-infected cells (100±19%). This indicates that the lipolytic activity of EL is not necessary for HDL binding. However, treatment with tetrahydrolipstatin significantly reduced HDL binding of endothelial cells infected with wild-type EL (AD-EL) and AD-LacZ by 58±15% and 76±6%, respectively, but not HDL binding of endothelial cells infected with lipolytic inactive EL (AD-MUT EL; Figure 4C ).
EL Enhancement After IL-6 Stimulation Causes Increased HDL Binding and Transport
To analyze whether IL-6-mediated induction of EL expression, as well as HDL binding and transport, is causally related; the endothelial cells were stimulated with IL-6 and treated with tetrahydrolipstatin to inhibit EL. IL-6 stimulation enhanced binding and transport of HDL to 140±20% and 184±30%, respectively. However, tetrahydrolipstatin treatment reduced the IL-6-stimulated binding and transport by 65±17% and 77±30%, respectively, compared with IL-6 stimulation alone. In nonstimulated cells, tetrahydrolipstatin reduced both binding and transport by 48±25% and 76±20%, respectively. The inhibitory effect of tetrahydrolipstatin on endothelial binding and transport of HDL did not differ significantly between IL-6-treated cells and untreated cells ( Figure 5A and 5B) . Moreover, IL-6 stimulation increased the lipase activity to 130±6% compared with the control, the IL-6 non-treated cells ( Figure 5C ). Transfection with specific siRNA against EL reduced the lipolytic activity by 43±30%, verifying that the lipolytic activity was exerted by EL (data not shown). Moreover, endothelial cells treated with tetrahydrolipstatin in the absence or presence of IL-6 exhibited reduced lipase activity by 58±5% and 57±7%, respectively, compared with the nonstimulated cells (100±9%; Figure 5C ). These results indicate that the upregulation of EL expression is responsible for the enhancement of cell binding and transport of HDL through endothelial cells after IL-6 stimulation. Likewise, tetrahydrolipstatin reduced HDL binding to endothelial cells after tumor necrosis factor α or IL-1β stimulation by the same degree as in nonstimulated cells ( Figure III in the online-only Data Supplement).
EL Activity Is Needed for HDL Transport
Next, we investigated the importance of the lipolytic activity of EL for HDL transport. The cells overexpressing wild-type EL (AD-EL) induced HDL transport by 244±94% compared with the control cells (AD-LacZ) 100±19% ( Figure 4D) . Interestingly, the cells overexpressing the mutated EL (AD-MUT EL), which showed similar HDL binding, did not increase HDL transport (98±21%) significantly beyond AD-LacZ-infected cells (100±19%; Figure 4D ). To rule out that the induction of HDL transport was because of the permeability changes after EL overexpression, the integrity of the endothelial cells monolayer was assessed by analyzing the permeability of 3 H-inulin after 1 hour of incubation. The permeability coefficients did not differ among cell layers infected with AD-EL (1.684±0.311×10 -5 cm/s), AD-MUT EL (1.628±0.168×10 -5 cm/s), and AD-LacZ (1.634±0.168×10 -5 cm/s).
EL Is Responsible for Size Reduction of HDL After Cell Contact
We previously demonstrated that the population of HDL particle transported through a monolayer of endothelial cells is changed to a reduced size. Gel filtration analysis of the transported HDL demonstrated a Stokes diameter of 9.74±0.25 nm, whereas the Stokes diameter of the starting HDL was of 10.63±0.06 nm ( Figure 6 ). Interestingly, the protein moiety was not changed as previously demonstrated by SDS-PAGE analysis. 6 To assess whether EL or SR-BI is responsible for the size reduction of HDL, we used pharmacological inhibitors, as well as RNA interference, against EL and SR-BI. After both interference with SR-BI siRNA and noncoding siRNA, transendothelial transport led to the recovery of smaller particles with Stokes diameter of 9.81±0.01 and 10.01±0.015 nm, respectively ( Figure 6 ). In contrast, after silencing of EL, the HDL-particles that were recovered in the basolateral compartment were less prominently and not significantly reduced in size (Stokes diameter of 10.25±0.12 versus 10.63±0.05 nm for HDL without cell contact; Figure 6 ). To corroborate this finding, we blocked the lipase activity of EL with tetrahydrolipstatin, which prevented the size reduction of HDL ( Figure 6 ). These data suggest that EL but not SR-BI contributes to the particle size reduction of HDL during transendothelial transport.
To investigate whether smaller HDL particles are preferentially transported, the transport of HDL 2 (1.063<d<1.125 kg/L) versus HDL 3 (1.125<d<1.21 kg/L) was analyzed. Interestingly, we could not observe any significant difference for the transport through or the binding to endothelial cells ( Figure V in the online-only Data Supplement).
Discussion
We previously reported that HDL is transported through a monolayer of cultivated endothelial cells in a specific process, which involves SR-BI and ABCG1. 6 Here, we assessed the question whether HDL binding, cell association, and transport through the endothelial cells are modulated by the proinflammatory cytokine IL-6. IL-6 strongly correlates with the development of atherosclerosis, [7] [8] [9] and its presence has been demonstrated in the atherosclerotic lesion. 21 Inflammatory cytokines have been demonstrated to modulate transendothelial transport of viruses and proteins. For example, Dohgu et al demonstrated an increase in HIV transport after IL-6 stimulation, whereas Wang et al in contrast showed a reduction of insulin transport after IL-6 stimulation. 22, 23 However, to our knowledge, we demonstrate for the first time that IL-6 enhances the capacity of endothelial cells to bind, to associate, and to transport HDL. Importantly, inflammatory cytokines, such as tumor necrosis factor α, IL-1β, or IL-6, have been demonstrated to increase the permeability of the endothelial barrier in a concentration and time-dependent manner. [24] [25] [26] Therefore in the present study, we ruled out that the concentration of IL-6 used enhances transport by increasing the permeability of the endothelial barrier. Also unlike in human peripheral monocytes, 27 IL-6 stimulation did not cause any changes in RNA or protein levels of SR-BI or ABCG1 in endothelial cells. These findings clearly indicate that the increased HDL binding and transport of HDL in IL-6-stimulated endothelial cells are not mediated by SR-BI or ABCG1 but by another protein. We hypothesized the involvement of EL that is produced and secreted by endothelial cells to be subsequently bound by heparan sulfate proteoglycan on the cell surface. 13 After confirming the expression of EL in the endothelial cells, its role in HDL binding, cell association, and transport was assessed using general pharmacological treatments and specific RNA interference.
Digestion of heparan sulfate proteoglycan with heparinase to release the bound EL or competition for EL binding to heparan sulfate proteoglycan with heparin reduced HDL binding on the cell surface. Moreover, the reduction in HDL binding after blocking EL activity by the general lipase inhibitor tetrahydrolipstatin corroborates the involvement of EL in HDL binding. Interestingly, in hepatocytes, it is reported that blocking EL by tetrahydrolipstatin induces the binding of HDL. 14 The role of EL in the binding of HDL was further confirmed by specific RNA interference against EL and showed a dramatic reduction in HDL binding. Specific knockdown of EL also demonstrated the involvement of EL in HDL internalization and transport of HDL through a monolayer of endothelial cells. These results clearly indicate EL as an important mediator of HDL binding in endothelial cells, as well as in hepatocytes. EL as member of the triglyceride lipase family was previously reported to bind lipoprotein via noncatalytic bridging effects. [13] [14] [15] [16] We confirmed the bridging effect of EL by demonstrating that overexpression of both catalytic active wild-type EL and inactive mutant EL increases endothelial HDL binding. These results suggest that the lipolytic activity of EL is not needed for HDL binding to endothelial cells. However, tetrahydrolipstatin treatment reduced HDL binding only in the cells overexpressing the catalytic active EL but not in the cells overexpressing the mutated EL. This suggests that in the active enzyme, tetrahydrolipstatin blocks sterically the interaction of HDL with the binding site in contrast to the mutant where the negatively charged Asp 192 is replaced by the uncharged Asn. Therefore, tetrahydrolipstatin is not able to bind and shield the binding site for HDL. We previously demonstrated that the mean population size of HDL particles was reduced during transendothelial transport without degradation of the protein moiety. 6 We hypothesized that either SR-BI or EL would be responsible for the effect. SR-BI is known to participate in transendothelial HDL transport. It is possible that the extraction of cholesteryl esters by the selective uptake 28 may also reduce the size of HDL. Therefore, we investigated whether SR-BI, EL, or both are responsible for the HDL particle size reduction in endothelial cells. Specific RNA interference experiments clearly showed that EL but not SR-BI is responsible for HDL particle size reduction. The finding was confirmed by blocking the lipolytic activity of EL with tetrahydrolipstatin. In contrast to HDL binding the lipolytic activity of EL is essential for HDL translocation through the endothelial monolayer because only the endothelial cells overexpressing the catalytically active EL revealed an enhanced HDL transport capacity. In addition, blocking the lipolytic function of EL by tetrahydrolipstatin in primary endothelial cells reduced the HDL transport. To test whether EL enhances HDL transport by generating smaller HDL, we compared the transport rates of HDL 2 and HDL 3 . The lack of any difference in the transport rates of HDL 2 and HDL 3 ( Figure V in the online-only Data Supplement) rules out this explanation. An alternative explanation is that lipolytic products generated by EL from HDL that are lysophospholipids or free fatty acids modulate transendothelial transport of HDL. For example, lysophospholipids generated by EL were previously shown to modulate endothelial vasorelaxation. 30 At first sight, the induction of both EL and transendothelial HDL transport by inflammatory cytokines produces a paradox because both inflammation and the low HDL-cholesterol levels associated with high EL activity are considered as proatherogenic. However, both gene targeting in mice and Mendelian randomization experiments in humans produced controversial results on the effect of EL on atherosclerosis and cardiovascular risk, respectively. [31] [32] [33] [34] [35] In addition, the lipolytic products generated by EL in HDL were previously shown to exert both putatively pro-and antiatherogenic activities. [36] [37] [38] [39] Indeed, Hara et al 37 reported that EL deletion resulted in increased HDL and anti-inflammatory function in the plasma compartment; Ahmed et al 39 showed that HDL lipolysis by EL mediates repression of vascular cell adhesion molecule 1 expression. In view of the many anti-inflammatory properties of HDL, 40 any increased transendothelial HDL transport and hence extravascular enrichment of HDL in inflammation may be a mechanism aimed at the resolution of tissue inflammation.
In conclusion, our study demonstrated for the first time an induction of HDL binding, cell association, and transport of HDL after IL-6 stimulation. By identifying EL as the endothelial target of IL-6 stimulation, we unraveled EL as a novel contributor to transendothelial HDL transport in addition to SR-BI and ABCG1. Furthermore, our data suggest that the lipolytic products generated by EL from HDL are important for HDL transcytosis. The physiological and pathological relevance of our findings needs to be tested (eg, by animal models).
